Abstract
Purified from a Mediterranean plant nearly two centuries ago, colchicine has been discovered to inhibit many steps in the inflammatory process. The drug has good oral bioavailability and some enterohepatic recirculation, requiring dose adjustments for kidney disease and avoidance in liver disease. Toxicities are primarily gastrointestinal, hepatic, and hematologic. Colchicine is approved by the U.S. Federal Drug Administration for the treatment and prophylaxis of gout flares but has also been tried with varying success in the treatment of familial Mediterranean fever, primary biliary cirrhosis, psoriasis, Behçet's disease, aphthous stomatitis, linear IgA dermatosis, relapsing polychondritis, Sweet's syndrome, scleroderma, amyloidosis, leukocytoclastic vasculitis, epidermolysis bullosa, and dermatomyositis.
| Original language | English (US) |
|---|---|
| Title of host publication | Annals of the New York Academy of Sciences |
| Pages | 766-773 |
| Number of pages | 8 |
| Volume | 1173 |
| DOIs | |
| State | Published - Sep 2009 |
Publication series
| Name | Annals of the New York Academy of Sciences |
|---|---|
| Volume | 1173 |
| ISSN (Print) | 00778923 |
| ISSN (Electronic) | 17496632 |
Fingerprint
Keywords
- Arthritis
- Gout
- Uric acid
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
Colchicine revisited. / Bhat, Anupama; Naguwa, Stanley M; Cheema, Gurtej S.; Gershwin, M. Eric.
Annals of the New York Academy of Sciences. Vol. 1173 2009. p. 766-773 (Annals of the New York Academy of Sciences; Vol. 1173).Research output: Chapter in Book/Report/Conference proceeding › Conference contribution
}
TY - GEN
T1 - Colchicine revisited
AU - Bhat, Anupama
AU - Naguwa, Stanley M
AU - Cheema, Gurtej S.
AU - Gershwin, M. Eric
PY - 2009/9
Y1 - 2009/9
N2 - Purified from a Mediterranean plant nearly two centuries ago, colchicine has been discovered to inhibit many steps in the inflammatory process. The drug has good oral bioavailability and some enterohepatic recirculation, requiring dose adjustments for kidney disease and avoidance in liver disease. Toxicities are primarily gastrointestinal, hepatic, and hematologic. Colchicine is approved by the U.S. Federal Drug Administration for the treatment and prophylaxis of gout flares but has also been tried with varying success in the treatment of familial Mediterranean fever, primary biliary cirrhosis, psoriasis, Behçet's disease, aphthous stomatitis, linear IgA dermatosis, relapsing polychondritis, Sweet's syndrome, scleroderma, amyloidosis, leukocytoclastic vasculitis, epidermolysis bullosa, and dermatomyositis.
AB - Purified from a Mediterranean plant nearly two centuries ago, colchicine has been discovered to inhibit many steps in the inflammatory process. The drug has good oral bioavailability and some enterohepatic recirculation, requiring dose adjustments for kidney disease and avoidance in liver disease. Toxicities are primarily gastrointestinal, hepatic, and hematologic. Colchicine is approved by the U.S. Federal Drug Administration for the treatment and prophylaxis of gout flares but has also been tried with varying success in the treatment of familial Mediterranean fever, primary biliary cirrhosis, psoriasis, Behçet's disease, aphthous stomatitis, linear IgA dermatosis, relapsing polychondritis, Sweet's syndrome, scleroderma, amyloidosis, leukocytoclastic vasculitis, epidermolysis bullosa, and dermatomyositis.
KW - Arthritis
KW - Gout
KW - Uric acid
UR - http://www.scopus.com/inward/record.url?scp=69949135704&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69949135704&partnerID=8YFLogxK
U2 - 10.1111/j.1749-6632.2009.04674.x
DO - 10.1111/j.1749-6632.2009.04674.x
M3 - Conference contribution
C2 - 19758227
AN - SCOPUS:69949135704
SN - 9781573317627
VL - 1173
T3 - Annals of the New York Academy of Sciences
SP - 766
EP - 773
BT - Annals of the New York Academy of Sciences
ER -